AstraZeneca backs online NHS passport tool
pharmafile | April 30, 2013 | News story | Medical Communications, Sales and Marketing | NHS, NIHR, app, medication passport
AstraZeneca has provided support to an NHS partner launching an online tool to help patients keep track of their health data.
The ‘My Medication Passport’ smartphone app and booklet are a result of a joint-working collaboration between the National Institute of Health Research (NIHR) for North West London (NWL), Imperial College Healthcare NHS Trust, and AstraZeneca.
The passport allows patients and carers to keep check of their medications by recording their name, dose, and timings – and also allows for changes in treatment and to facilitate the communication of medical information between patients and healthcare professionals.
NIHR CLAHRC for NWL’s director Professor Derek Bell, said: “I and the NIHR CLAHRC have been privileged to be part of this work. It reflects the drive and commitment of patients to work with healthcare professionals to make beneficial and rapid changes in healthcare delivery.”
AstraZeneca provided expertise and resources for the passport tool which is available as an app via the Android or iPhone marketplace. Both booklet and electronic versions enable patients to add details such as allergies and sensitivities, dates of vaccinations and screenings, home treatments and medication aids as well as hospital information if warranted.
The passport offering is supported by an ongoing evaluation programme which focuses on the use of it within practice, and the impact it has on patients and healthcare workers.
Fran Husson, who is a patient representative with NIHR CLAHRC for NWL, added: “Patient and Public Involvement informs all CLAHRC activities and projects to improve healthcare using innovative methods.
“It is therefore not surprising that a group of patients working very closely with front line medical staff on quality improvement projects developed My Medication Passport, which brings a new dimension to care by empowering the patient to understand and manage medications across different care settings.”
Brett Wells
Related Content
First 90 days of antipsychotic treatment linked to rapid metabolic changes
The first 90 days after starting antipsychotic treatment are a critical period for monitoring blood …
“That gap between innovation and delivery was what stood out to me most”
Pharmafile chats with Camunda’s Natosha McNeal about the vital role of delivery, onboarding AI and …
Fortysomethings’ non-attendance at NHS Health Checks raises concerns, says study
People in their forties account for almost three-quarters of those who do not attend NHS …
